GSK 2801

Discontinued Product

GSK 2801 (Cat. No. 5635) has been withdrawn from sale for commercial reasons.
Description: Selective BAZ2A and BAZ2B inhibitor
Chemical Name: 1-[1-[2-(Methylsulfonyl)phenyl]-7-propoxy-3-indolizinyl]ethanone
Purity: ≥98% (HPLC)
Literature (4)

Biological Activity for GSK 2801

GSK 2801 is a selective BAZ2A and BAZ2B inhibitor (IC50 values are 0.40 and 0.43 μM, respectively). Selective for BAZ2A/B over TAF1L and BRD9. Cell permeable and orally available.

Licensing Information

This probe is supplied in conjunction with the Structural Genomics Consortium. For further characterization details, please visit the GSK 2801 probe summary on the SGC website.

External Portal Information for GSK 2801 is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of GSK2801 is reviewed on the chemical probes website.

Technical Data for GSK 2801

M. Wt 371.45
Formula C20H21NO4S
Storage Store at -20°C
Purity ≥98% (HPLC)
CAS Number 1619994-68-1
PubChem ID 73010930
Smiles CCCOC1=CC2=C(C3=C(S(C)(=O)=O)C=CC=C3)C=C(C(C)=O)N2C=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for GSK 2801

References are publications that support the biological activity of the product.

Chen et al (2015) Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B. J.Med.Chem PMID: 25799074

View Related Products by Target

View Related Products by Product Action

View all Bromodomain Inhibitors

Keywords: GSK 2801, GSK 2801 supplier, selective, bromodomain, inhibitors, inhibits, cell, permeable, orally, bioavailable, BAZ2A, BAZ2B, structural, genomics, consortium, SGC, GSK2801, Bromodomains, 5635, Tocris Bioscience

Citations for GSK 2801

Citations are publications that use Tocris products.

Currently there are no citations for GSK 2801.

Reviews for GSK 2801

There are currently no reviews for this product. Be the first to review GSK 2801 and earn rewards!

Have you used GSK 2801?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Stem Cell Research Product Guide

Stem Cell Research Product Guide

This product guide provides a background to the use of small molecules in stem cell research and lists over 200 products for use in:

  • Self-renewal and Maintenance
  • Differentiation
  • Reprogramming
  • Organoid Generation
  • GMP and Ancillary Material Grade Products
Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.